Burden of Diabetic Nephropathy in China Shows No Signs of Abatement
The burden of diabetic nephropathy (DN) in China continues to rise, posing a significant public health challenge and negatively impacting the quality of life of millions of people. According to a recent study using the Global Burden of Disease (GBD) system, the number of DN cases in China reached 20,911,520 in 2021, with an age-standardized prevalence rate of 1,053.92 per 100,000 people.
Key Takeaways:
- The study found that the burden of DN in China increased from 1990 to 2021, with a total of 20,911,520 cases reported in 2021.
- The age-standardized incidence rate (ASIR) of DN was 16.29 per 100,000 people in 2021, while the age-standardized death rate (ASDR) was 5.64 per 100,000 people.
- The age-standardized disability-adjusted life years (DALYs) of DN were 122.15 per 100,000 people in 2021.
- The incidence rate of DN showed a sustained upward trend from 1990 to 2021, and predictive analysis suggests that the ASIR will continue to rise from 2022 to 2036.
- The study found that population aging was the main cause of the increased burden of DN in China.
Statistics:
- 20,911,520: The total number of DN cases in China in 2021.
- 1,053.92: The age-standardized prevalence rate of DN in China in 2021.
- 16.29: The age-standardized incidence rate of DN in China in 2021.
- 5.64: The age-standardized death rate of DN in China in 2021.
- 122.15: The age-standardized disability-adjusted life years (DALYs) of DN in China in 2021.
Sources:
- Long-term trends and future projections of the burden of diabetic nephropathy in China: a comprehensive analysis of GBD data from 1990 to 2036. Frontiers in Endocrinology, 2025;16:1681689.
- NewsRx. New Global Burden of Disease Findings from Gansu University of Chinese Medicine Discussed (Long-term trends and future projections of the burden of diabetic nephropathy in China: a comprehensive analysis of GBD data from 1990 to 2036). Diabetes Week. November 3, 2025; p 220.